2021
The demise of islet allotransplantation in the United States: A call for an urgent regulatory update
Witkowski P, Philipson L, Kaufman D, Ratner L, Abouljoud M, Bellin M, Buse J, Kandeel F, Stock P, Mulligan D, Markmann J, Kozlowski T, Andreoni K, Alejandro R, Baidal D, Hardy M, Wickrema A, Mirmira R, Fung J, Becker Y, Josephson M, Bachul P, Pyda J, Charlton M, Millis J, Gaglia J, Stratta R, Fridell J, Niederhaus S, Forbes R, Jayant K, Robertson R, Odorico J, Levy M, Harland R, Abrams P, Olaitan O, Kandaswamy R, Wellen J, Japour A, Desai C, Naziruddin B, Balamurugan A, Barth R, Ricordi C, Collaborative T. The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. American Journal Of Transplantation 2021, 21: 1365-1375. PMID: 33251712, PMCID: PMC8016716, DOI: 10.1111/ajt.16397.Peer-Reviewed Original ResearchMeSH KeywordsBiological ProductsCosts and Cost AnalysisDiabetes Mellitus, Type 1HumansIslets of Langerhans TransplantationTransplantation, HeterologousUnited StatesConceptsRegulatory frameworkUnited StatesIslet allotransplantationStandard-of-care procedureUS clinical practiceClinical practiceType 1 diabetes mellitusRegulatory distinctionsMinimally manipulated tissuesInvestigation proceduresRegulatory updatesClinical trialsBiological drugsDecades of progressPatientsAllotransplantationIslet transplantationTransplantationIsletsHuman isletsRegulationDrugHuman cellsImminent demiseState
1998
Cost analysis of four strategies for prevention of CMV infection in liver transplant recipients
Post AB, Mulligan DC, Bush W. Cost analysis of four strategies for prevention of CMV infection in liver transplant recipients. Transplantation Proceedings 1998, 30: 2102-2103. PMID: 9723406, DOI: 10.1016/s0041-1345(98)00553-3.Peer-Reviewed Original Research